Initial iQ-007 IND-Enabling Tox Results Accelerate Prep for First in Human Phase 1 Study
Princeton, NJ, March 19, 2024 ─ iQure Pharma Inc. (iQure), a US-based global biotech, announced that its asset, iQ-007, a novel...
top of page
News
Search
Jan 23
iQure Pharma Awarded Its First Patent for iQ-008, a Novel Analgesic Compound to Treat Neuropathic Pain
Princeton, NJ, January 23, 2024 ─ iQure Pharma Inc. (iQure), a US-based global biotech, announced that its asset, iQ-008, a novel...
Dec 22, 2023
iQure Pharma Attending JPM Week in San Francisco — January 8-12, 2024
Princeton, NJ, December 22, 2023 ─ iQure Pharma Inc. (iQure), a U.S.-based pre-clinical drug discovery company focusing on central...
Nov 28, 2023
iQure Pharma Announces Impressive Second Close of Oversubscribed Series A Financing
Princeton, NJ, 28 November, 2023 ─ iQure Pharma Inc, (iQure) a trailblazing pre-clinical drug discovery company focusing on central...
Oct 11, 2023
iQure Pharma Secures Funding from Ventura BioMed Investors and OKG Capital
Princeton, NJ, October 11, 2023 ─ iQure Pharma Inc. (iQure), a CNS company dedicated to the development of new epilepsy and pain...
Jul 5, 2023
iQure Pharma Awarded Second Patent for iQ-007, Novel Therapy to Treat Neuropathic Pain & Epilepsy
Princeton, NJ, July 6, 2023 ─ iQure Pharma Inc. (iQure), a US-based global biotech company, has been awarded a second patent for...
Dec 14, 2022
iQure Pharma Attending JPM Week in San Francisco — January 9-12, 2023
Princeton, NJ, December 14, 2022 ─ iQure Pharma Inc. (iQure), a US-based global biotech company, is attending the 41st Annual J.P. Morgan...
Sep 18, 2022
iQure Pharma Selected to Join NYU Stern Endless Frontier Labs (EFL) 2022-2023 Life Sciences Track
iQure Pharma is one of 25 companies invited to join the NYU Stern School of Business Endless Frontier Labs 2022-2023 cohort dedicated to...
Aug 30, 2022
iQure Pharma Secures $600K in Commitments in Early Closing to Research Neuropathic Pain Therapies
Keiretsu Forum and Business Angel Investors Provide Funding to Support Research into Neuropathic Pain Compounds iQ-007 and iQ-008...
Apr 7, 2022
iQure Pharma Targets Future with New Board Appointments
Life Sciences industry experts Michael D. Webb and Brian Cain bring extensive expertise in strategic pharmaceutical growth DELAWARE,...
Mar 1, 2022
iQure Pharma Will Present at Mid-Atlantic Diamond Venture 2022 Spring Forum
DELAWARE, March, 2022 ─ iQure Pharma Inc. (iQure), a US-based biotech company, has been invited to present at the Mid-Atlantic Diamond...
Feb 16, 2021
Company signed Agreement with University of Arizona for non-opioid treatment of post-operative pain
Delaware – February 2021, iQure Pharma Inc. (iQure), a company dedicated to the development of novel therapeutics in the area of pain...
Sep 14, 2020
iQure Pharma Inc. Secures Private Investment of $100,000
Delaware – September 2020, iQure Pharma Inc. (iQure), a company dedicated to preclinical and early clinical development of new...
May 25, 2020
iQure Pharma Inc. Secures Additional Investment of $50,000
Delaware – May, 2020, iQure Pharma Inc., a company dedicated to preclinical and early clinical development of new therapeutics, recently...
Dec 16, 2019
Chairman Dr. Peter Schiemann, will participate at JPMorganBIO in San Francisco 12.-16. January
Chairman of the Board, Dr. Peter Schiemann, will participate at JPMorganBIO in San Francisco 12.-16. January
JPM Week
No Abuse
bottom of page